Menaquinone Synthase Inhibitors

The specific aims for the initial 18 months of this proof of concept program are as follows: In vivo target validation by genetic deletion of MenA; Relate the ability of the lead compounds to kill M.tb to their ability to inhibit the presumed target, MenA; Medicinal chemistry improvement of the lead series and selection of a compound suitable for a pharmacologic proof-of-concept in the mouse; and In vivo pharmacologic proof of concept.